Last updated: 2026-09-16 09:46:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Liquidia Corporation (LQDA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $64,24, with a market capitalisation of $5,85B and a P/E ratio of 42,44. Over the past 52 weeks, its price has ranged from $21,15 to $93,61. This page covers its latest market performance, valuation, price trends and company information.
$5,85B | |
$63,70 | |
$93,61 | |
$2,25 | |
$65,72 | |
102,00 | |
1,69M | |
42,44 | |
$93,61 | |
$21,15 | |
-- | |
-- |
Liquidia Corporation (LQDA) is trading at $64,24 in pre-market trading as of 2026-09-16 09:20:00, down 2,26% ($1,48) from the previous close of $65,72
Pre-market trading shows how investors are pricing LQDA before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Liquidia Corporation (LQDA) moved from $68,66 to $64,24, representing a decline of 6,44% ($4,42).
The stock traded between $62,86 and $69,94 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,06 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 59,5%
LQDA is currently trading at $64,24, placing it 59,5% of the way from its 52-week low of $21,15 to its 52-week high of $93,61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 216 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Liquidia Corporation (LQDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.